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Introduction
Diabetes mellitus (DM) is one of the most crucial risk 
factors for morbidity and mortality from coronary heart 
disease (CAD) in the modern world. 25-30% of patients 
with acute coronary syndromes are diagnosed with DM 
[27]. Clinical manifestations of CAD develop earlier in pa-
tients with DM and are associated with a worse prognosis 
compared with patients without diabetes. CAD associated 
mortality in patients with DM is two times higher than 
that in patients without diabetes [31]; CAD is the cause of 
death of three out of four patients with DM [25]. This allows 
characterizing DM as an equivalent of CAD with already 
suffered myocardial infarction (MI) in terms of the risk of 
coronary events [18]. Clinical manifestations of CAD often 
call for a specific medical therapy and revascularization in 
patients with DM. On the other hand, concomitant DM is 
present in almost 40% of patients with CAD who undergo 
coronary artery bypass grafting (CABG) [27]. The existing 
evidence base and existing clinical experience allow us to 
summarize the current state of the problem of myocardial 
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Abstract
Background: Diabetes mellitus (DM) is one of the most crucial risk factors for morbidity and mortality from coronary heart disease (CAD) in the 
contemporary world. The prevalence and rapid progression of atherosclerotic lesions leading to worse survival is a defining feature of the course of CAD 
in patients with DM. Clinical manifestations of CAD often call for revascularization in patients with DM. The contemporary data regarding efficacy of 
the coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) in patients with CAD and concomitant DM are summarized 
in the review. 
Conclusions: Worse survival prognosis in case of CAD with concomitant DM is associated with systemic atherosclerosis, presence of a number of 
concomitant risk factors, as well as masked clinical manifestations of ischemia and myocardial infarction common for the patients with DM. The combination 
of CAD and DM once again proves the benefit of the long-term use of drugs for the secondary prevention of cardiovascular events. From the standpoint 
of evidence-based medicine the optimal method of revascularization in CAD patients with multivessel coronary artery disease and concomitant DM is 
CABG surgery. In FREEDOM study surgical myocardial revascularization reduced the number of endpoints compared to PCI. In the case of PCI it is 
advisable that eluting stents reducing the likelihood of restenosis and the need for repeated revascularization be used.
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Diagnosis and the course of CAD in  
patients with DM
Rapid progression and prevalence of atherosclerotic le-
sions in the presence of DM is accounted for by a number 
of adverse effects associated with hyperglycemia, insulin re-
sistance and dyslipidemia. These include, in particular, en-
hancement of lipid uptake by macrophages, leading to the 
formation of foam cells, endothelial dysfunction, platelet 
activation, increased activity of proteolysis processes, and 
stimulation of smooth muscle cell proliferation, fibrosis and 
systemic inflammation [29]. Insulin resistance and hyper-
insulinemia are associated with other risk factors for CAD, 
such as impaired glucose tolerance, hypertriglyceridemia, 
a decrease in high-density lipoprotein cholesterol, and ar-
terial hypertension. At the same time, isolated hyperinsu-
linemia has recently been considered an independent car-
diovascular risk factor [33]. 
Patients with DM are more likely to have lesions of the 
left coronary artery and multivessel coronary arteries; they 
also have more lipid-rich and prone to rupture atheroscle-
rotic plaques [27]. Factors that can determine worse surviv-
al prognosis of diabetic patients are diffuse atherosclerotic 
lesions of the small coronary arteries, the presence of many 
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associated risk factors, in particular kidney damage, and 
masking of clinical manifestations of ischemia in patients 
with DM. Consequently, even with the expansion of choice 
of medical and interventional treatment, the prognosis in 
patients with DM and already formed cardiovascular dis-
ease is significantly worse than in those without it. 
Methods to diagnose CAD in patients with DM do not 
differ essentially from those used in patients without dia-
betes. Patients with DM often have symptoms atypical for 
ischemia, or painless course of CAD. The main non-invasive 
method of examination in the presence of chest pain is a 
stress test on a bicycle ergometer or treadmill; out-patient 
ECG monitoring may have additional significance in cer-
tain situations (for example, during nighttime or morning 
painful attacks). In patients with DM the initial probabil-
ity of CAD is higher than in those without it. This, in turn, 
may affect the informative value of instrumental methods of 
CAD diagnostics. For example, with a positive test result in 
a patient with DM and atypical pain, the probability of CAD 
is higher than in a patient without diabetes. However, ob-
taining a negative result in many cases allows discontinuing 
the examination [33]. In doubtful situations, it is possible to 
use the most sensitive and highly specific methods for CAD 
diagnostics and myocardial viability assessment; in particu-
lar, single-photon emission computed tomography (SPECT) 
with thallium-201 or sestamibi, or stress echocardiography 
with exercise or dobutamine stress echocardiography.
The potential for reducing CAD associated mortality in 
patients with type 2 diabetes largely depends on how well 
risk factors are being corrected, including the use of modern 
antihypertensive and hypolipidemic agents [16]. The com-
bination of CAD with DM is an additional strong reason 
for the secondary prevention of cardiovascular events with 
antiplatelet agents, beta-blockers, statins and renin-angio-
tensin system blockers [34]. Yet, the greatest hopes for the 
improvement of the course of CAD in patients with DM are 
associated with surgical or endovascular myocardial revas-
cularization. Nevertheless, even in the case of percutane-
ous coronary interventions (PCI) or coronary artery bypass 
grafting (CABG), the survival prognosis of patients remains 
worse compared with those without diabetes [29].
Patients with DM who have undergone CABG in our 
clinic demonstrated hemodynamically significant stenoses 
of the right and circumflex coronary arteries more often. In 
these patients a greater number of postoperative complica-
tions were recorded (in particular, nephropathy and post-
operative atrial fibrillation) compared with those without 
DM [1]. It is the presence of a diffuse lesion of the coronary 
bed that explains the high probability of restenosis caused 
by neointimal hyperplasia following PCI in the presence of 
DM. To a certain extent the frequency of restenosis was re-
duced due to the introduction of eluting stents (with a drug 
coating). However, even with the widespread use of this 
modern technology of endovascular treatment, DM is as-
sociated with poor clinical outcomes. DM appeared one of 
the most powerful predictors of stent thrombosis in a meta-
analysis of 47 studied factors [12].
The information on the effect of DM on the outcomes 
of interventions is mainly based on the data from observa-
tional studies, registers, retrospective analyses of subgroups 
of patients with DM in large controlled studies of the effec-
tiveness of revascularization, as well as studies comparing 
the effectiveness of PCI and CABG. Only in some studies, 
though, interventional treatment of CAD in patients with 
DM was given special consideration to.
Revascularization or medical treatment?
Generally, the indications for myocardial revascular-
ization in patients with DM do not differ drastically from 
those in patients without it. In particular, a meta-analysis of 
nine randomized clinical trials involving 9904 patients with 
acute coronary syndrome did not reveal any dependence of 
the benefit of revascularization in the presence of DM [28]. 
At the same time the absolute risk reduction was larger with 
concomitant diabetes compared with patients without DM. 
BARI 2D study included patients with type 2 diabetes 
and hemodynamically significant stenosis of at least one 
coronary artery. Half of the patients had stable angina, 10% 
had unstable angina, and 18% did not have angina or its 
equivalents. Patients with indisputable indications for re-
vascularization (for example, multi-vessel lesion with LVD) 
were not included. In all cases, intensive drug therapy was 
carried out to correct hyperglycemia, dyslipidemia, hyper-
tension, reduce angina, as well as modify lifestyle. On evalu-
ating the coronary angiography data, the cardiologist chose 
the potentially most appropriate method of revasculariza-
tion: PCI or CABG followed by randomization into groups 
of drug treatment or revascularization. Consequently, PCI 
was mainly performed in patients with a lesion of one or 
two vessels (two-thirds of the participants), while patients 
with a three-vascular lesion underwent CABG [15].
At the same time, among high-risk patients selected for 
CABG surgery, revascularization reduced the incidence of 
major cardiovascular events (22% versus 31%, p = 0.01) and 
non-fatal MI (7% versus 15%, p <0.01). Thus, for the first 
time it was shown that in stable patients with coronary ath-
erosclerosis, CABG operation reduced the risk of the future 
non-fatal MI, while in the low-risk patients selected for PCI, 
immediate revascularization did not improve outcomes. 
The results obtained in BARI 2D study agreed with the data 
from COURAGE study and other studies in which most pa-
tients did not have DM [4, 9].
It is worth noting that BARI 2D study did not include 
patients with initial coronary atherosclerosis (without con-
vincing indications for revascularization) on the one hand, 
and, on the other hand, patients with severe symptoms or 
pronounced stenotic coronary arteriosclerosis (therefore, 
absolute indications for revascularization). Thus, the results 
of this study are most relevant to patients with moderate or 
stable symptoms and /or moderately pronounced athero-
sclerotic changes in the coronary bed. Moreover, approxi-
mately 40% of patients randomized for drug treatment, dur-
ing 5 years of follow-up, were actually revascularized due 
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to the progression of angina, acute coronary syndrome or 
severe myocardial ischemia. Only a third of the patients in 
the PCI group had eluted stents implanted; in most cases, 
conventional metal stents were used [31].
Surgical revascularization of percutaneous 
intervention?
BARI 2D study did not attempt to compare the effective-
ness of CABG and PCI, because the groups of patients who 
used various methods of revascularization differed signifi-
cantly in angiographic characteristics. The first attempt to 
answer this question was made in the original BARI study, in 
which 1.829 patients (mostly with unstable angina and mul-
tivessel CAD) were randomized to CABG or PCI groups (at 
that time – balloon angioplasty) [6]. No differences in death 
rates or MI were revealed in the compared groups in this 
study. However, in patients with concomitant DM such dif-
ferences were found. In particular, the mortality of patients 
with diabetes and CAD with lesions of one or two vessels of 
coronary arteries during 5 years of the follow-up was 35% 
in the PCI group and 19% after CABG [7]. CABG was gen-
erally associated with significantly better survival over five 
(80% vs. 67%) and ten years (respectively, 58% vs. 46%, p = 
0.025) compared with balloon angioplasty [7,8]. Undoubt-
edly, the use of CABG was determined by the use of arterial 
mammary shunts in 81% of cases. The results of BARI study 
and some retrospective analyses showed that the presence 
of DM can affect not only the outcomes of revascularization 
interventions, but also the choice between CABG and PCI.
The results of retrospective analyses also testified to the 
possible advantages of CABG in comparison with PCI in 
terms of the effect on mortality within 5 years in patients 
with CAD and DM [10]. The use of PCI with stent implanta-
tion is often associated in patients with DM with the forma-
tion of restenosis. In CARDia study involving 510 patients 
with DM during a one year observation, the use of stents 
was accompanied by a greater incidence of restenosis and 
repeated revascularization compared with CABG [24]. 
Despite the obvious limitations of retrospective analyses, 
the existing evidence base testified in favor of performing 
CABG (and not PCI) as a more reliable method for myocar-
dial revascularization in patients with three-vascular lesion 
or stenosis of the left coronary artery. In particular, in the 
subgroup of 452 patients with DM and multivessel lesions 
of coronary arteries in the SYNTAX study with a 5-year fol-
low-up, no differences between the CABG and PCI groups 
were found in terms of incidence of “large” cardiovascular 
complications; however, the need to repeat revasculariza-
tion was more common in the PCI group [27].
It can be assumed that concomitant DM does not affect 
the patency of arterial (mammary) shunts, in contrast to 
venous shunts, where rapid progression of atherosclerotic 
lesions was observed [32]. Moreover, a lower incidence of 
non-fatal MI in BARI-2D study [15] revealed that bypass 
surgery, unlike endovascular interventions, helps to prevent 
the progression of coronary artery lesions and / or rupture 
of atherosclerotic plaque in proximal regions [2]. However, 
despite these arguments, the percentage of PCI in patients 
with diabetes continued to increase. Obviously, this para-
doxical phenomenon was brought about by the advance-
ment of the eluting stents technology, as well as a frequent 
instant implementation of angiography and PCI, without a 
proper discussion and giving the patient full information to 
make a reasonable decision [21].
A FREEDOM study conducted by the United States 
National Heart, Lung, and Blood Institute randomized pa-
tients with DM and multivessel CAD into PCI groups with 
implantation of eluting stents (such as sirolimus or pacli-
taxel) or CABG surgery (2.9 shunt per patient, 94.4 % of 
cases used arterial shunts) [14]. The study included patients 
with hemodynamically significant stenosis (more than 
70%) of two or more coronary arteries, but without stenosis 
of the left coronary artery trunk. Only about a quarter of 
patients had previously suffered MI, in the overwhelming 
majority of cases, the left ventricular (LV) ejection fraction 
(EF) was preserved (i.e., there were no convincing indica-
tions for surgical revascularization). The observation lasted 
at least two years, on average – 3.8 years. All patients were 
prescribed modern medical therapy to control low-density 
lipoprotein cholesterol level (target value less than 70 mg%), 
blood pressure (less than 130/80 mm Hg) and glycosylated 
hemoglobin (less than 7%). The primary endpoint was the 
sum of death outcomes, non-fatal MI, or stroke.
A total of 1900 patients were included (mean age 63.1 ± 
9.1 years, 29% – women), with 83% having a three-vessel le-
sion. The frequency of reaching the primary endpoint after 
CABG was 30% less: in the CABG group it made up 18.7%, 
after PCI – 26.6% (P = 0.005). The effect of CABG was 
achieved by reducing MI frequency (10.9% versus 16.3%, 
P <0.001) and death from any cause (6.0% versus 13.9%, P 
= 0.049). Yet, strokes developed more often in the CABG 
group than after stenting (5.2% vs. 2.4%, P = 0.03), mainly 
occurring in the early postoperative period.
FREEDOM study was the most significant stage in the 
discussion on the choice of the optimal method of revas-
cularization in patients with DM. CABG surgery provided 
better results than PCI due to a decrease in the frequency of 
end points [14]. A little later, similar results were obtained 
in VACARDS study [23], where a comparison of CABG and 
PCI was also conducted in patients with DM. Due to the 
early termination of the study, a total of only 198 patients 
were randomized. Deaths, or non-fatal MI cases occurred 
in 18.4% of patients in the CABG group and 25.9% in the 
PCI group (P <0.05).
A certain limitation to the use of data from FREEDOM 
study was a relative “mildness” of patients in terms of the 
frequency of previous MI, severity of LV dysfunction, and 
clinical manifestations of heart failure. To a certain extent, 
this limitation was overcome in a recently published analy-
sis of outcomes in 11.518 patients with LV ischemic dys-
function, conducted as a part of a register in the Canadian 
province of Alberta [19]. The difference between CABG and 
PCI in terms of the overall influence on mortality rate was 
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evident in patients with DM (10.7 and 15.7% respectively, 
P = 0.0001) and was absent in patients without it (8.4 and 
8.7%, unreliable differences). Among 2387 patients with 
DM, “matches” with similar clinical characteristics were 
specifically selected who underwent CABG or PCI [26]. The 
frequency of “major” cardiovascular complications, as well 
as death from all causes was greater in the cohort of patients 
with EF less than 35% and 35-49%. The incidence of stroke 
did not differ in the CABG and PCI groups, regardless of 
EF indicator. PCI was associated with a greater incidence of 
MI in the cohort of patients with low EF, whereas repeated 
revascularization was more often recorded after PCI in co-
horts with EF less than 35% and 35-49%. The authors con-
cluded that CABG is more expedient in terms of the effect 
on the risk of cardiovascular complications and the survival 
of patients with DM and LVD.
Favorable effects of CABG compared with PCI were also 
confirmed in a recently published analysis of the results of 
treatment of patients after acute coronary syndrome in real 
clinical practice [30]. In a systematic analysis of the results 
of interventional treatment of 13114 patients with type 2 
diabetes cases of major adverse events, repeated revascular-
ization and MI were observed more often in the PCI group 
than after CABG [11]. It should be noted that groups of pa-
tients with and without DM do not differ in the incidence of 
early stent thrombosis; at the same time, DM is associated 
with a greater incidence of late thrombosis compared with 
patients without diabetes [38].
Obviously, the type of stents used can have a significant 
impact on the results of PCI in patients with DM. In par-
ticular, in the New York State register, the use of everolim-
us-type stents was associated with a similar risk of death, a 
higher risk of MI (in case of incomplete revascularization) 
and repeated revascularization, and a lower risk of stroke 
compared to isolated CABG [3]. In general, the existing 
evidence base testifies in favor of CABG, rather than PCI, 
in patients with DM and multivessel CAD [22, 36]. Basing 
on the available data, patients with DM should be informed 
about the benefits of CABG for improvement of survival 
prior to coronary angiography. If there is a concomitant pa-
thology which causes an increased risk of surgery, an indi-
vidualized decision regarding the type of revascularization 
should be made by a multidisciplinary team of specialists 
based on a comparison of the advantages and disadvantages 
of various methods [20, 27].
Consensus recommendations and contradicting 
aspects of patient management
Feasibility of sensitive heart stress-visualization methods 
to detect MI has not yet been proved in asymptomatic pa-
tients with DM who have no past history of coronary events 
[17, 37]. In such cases optimal drug therapy aimed at the 
primary prevention of cardiovascular events remains the 
method of choice [34]. Detection of LV dysfunction, high-
risk criteria according to the exercise test, as well as cases of 
insufficient effectiveness of drug therapy form the basis for 
coronary angiography in patients with anginal attacks (fig. 
1). Basing on the results of BARI 2D study, patients with one 
or two vascular lesions of coronary arteries associated with 
stable manifestations of MI can continue conservative treat-
ment, while in case of destabilization of ischemia or emer-























Fig. 1.  Algorithm for management of patients with stable angina  




The advantages and disadvantages of various treatment strategies for 
patients with moderate CAD with concomitant DM (adapted from [31]) 
Compared criteria Drug therapy PCI CABG 
Symptom control Moderate  Good  Good  
Primary or repeated revascularization 
over 5 years 
42% (BARI 2D 
study) 
30% 9% 
Repeated revascularization over 1 year ------------ 12-20% 2-6% 
Mortality risk Reference Similar Similar 
MI risk  Reference Similar Lower 
Non-fatal stroke Not known 0.4-0.9% 2.5-2.8% 
Hospital stay and rehabilitation Reference Days Weeks and months 
Quality of life in a year Reference Similar Better 
Extent of revascularization  ------------ Moderate Good  
Cost-effect ratio:  
Over 4 years 
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Lesion of one or two 
vessels without 
LADA lesion 
Trunk lesion, lesion 
of two or three 
vessels, including 




Fig. 1.  Algorithm for management of patients with stable angina  
with / without concomitant DM. LADA – Left Anterior Descending Artery.
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myocardial revascularization or PCI should be considered. 
Finally, in patients with multivessel CAD in the presence of 
DM, surgical myocardial revascularization has advantages 
over PCI, which has been primarily, indicated by the results 
of BARI 2D and FREEDOM studies [14, 15].
In any case, the decision on the treatment strategy and 
the choice of revascularization method in particular should 
be made taking into account the patient’s opinion, not only 
the information about the anatomy of coronary bed and the 
point of view of the attending physicians. For many patients, 
objective, balanced information about the expected length 
of stay in the clinic, recovery time, quality of life, risk of 
stroke, as well as the possible need for re-revascularization 
is crucial to make a final decision (tab. 1).
Table 1
The advantages and disadvantages of various treatment 
strategies for patients with moderate CAD with 
concomitant DM (adapted from [31])
Compared criteria Drug 
therapy
PCI CABG
Symptom control Moderate Good Good 
Primary or repeated revas-







Mortality risk Reference Similar Similar
MI risk Reference Similar Lower
Non-fatal stroke Not known 0.4-0.9% 2.5-2.8%
Hospital stay and rehabili-
tation
Reference Days Weeks and 
months
Quality of life in a year Reference Similar Better










In the European recommendations for myocardial re-
vascularization in 2018, a special section is devoted to the 
features of treatment of patients with DM [27]. First of all, 
this document clearly states that anatomical indications for 
revascularization in patients with DM are the same as in 
patients without it. In stable patients with CAD multivessel 
coronary artery disease and / or lesion of the left coronary 
artery is an argument in favor of CABG, rather than PCI.
Management problems and worse outcomes in patients 
with DM who previously underwent surgical myocardial re-
vascularization or endovascular interventions are due to the 
progressive nature of atherosclerotic vascular lesions, se-
vere endothelial dysfunction, platelet activation and blood 
clotting disorders [34]. These pathophysiological features 
determine the priorities of additional drug therapy after re-
vascularization, with particular attention to the treatment 
of associated diseases and correction of risk factors [16]. 
However, there has been no convincing data on the effect of 
glycemia on the frequency of restenosis after PCI or the pa-
tency of shunts after CABG surgery so far. Special attention 
is given to the assessment of renal function before angiog-
raphy in patients receiving metformin, with the suspension 
of the drug for 48 hours before the study in the presence of 
renal failure, and in other patients – in case of deterioration 
in renal function after angiography [27]. 
Undoubtedly, the use of renin-angiotensin system block-
ers, beta-blockers, antiplatelet agents after revascularization 
in patients with DM seems expedient.  Aggressive control 
of the lipid profile by drugs from statin group, whose dose 
in patients with a very high level of risk (including  pa-
tients with CAD and DM) is determined depending on the 
achievement of the target level of low-density lipoprotein 
less than 1.8 mmol/l also seems reasonable [13, 35].
European Survey Study on Coronary Revascularization 
assessed the potential impact of the presence of DM on the 
physician’s choice of drug treatment or revascularization. It 
has been found that DM was not included in the list of the 
main factors determining the physician’s decision in case of 
a stable course of CAD [5]. It should be noted that when 
choosing the revascularization method for patients with 
DM high probability of restenosis after PCI should be taken 
into account [34].
Conclusions
The prevalence and rapid progression of atherosclerotic 
lesions is a defining feature of the course of CAD in patients 
with DM. Worse survival prognosis in case of concomitant 
DM is associated with systemic atherosclerosis, presence 
of a number of concomitant risk factors, as well as masked 
clinical manifestations of ischemia and MI common for 
patients with DM. The combination of CAD and DM once 
again proves the benefit of the long-term use of drugs for the 
secondary prevention of cardiovascular events. From the 
standpoint of evidence-based medicine the optimal method 
of revascularization in CAD patients with multivessel coro-
nary artery disease and concomitant DM is CABG surgery. 
In FREEDOM study surgical myocardial revascularization 
reduced the number of endpoints compared to PCI. In the 
case of PCI it is advisable that eluting stents reducing the 
likelihood of restenosis and the need for repeated revascu-
larization be used.
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